GIlead Sciences (GILD) stock is trading at record highs after announcing a top- and bottom-line beat for the fourth quarter ...

Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? Over the past ...

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results , with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of ...

Family and consumer sciences professionals shape lives daily, support communities and quietly power some of the country’s most essential industries. For years, the value of that work has been clear to ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Morgridge Hall opened to UW-Madison students this semester. It houses the School of Computer, Data and Information Sciences. The new building is entirely donor-funded, the second such project on ...

Achieve Life Sciences is a late-stage pharma company awaiting FDA approval for Cytisinicline, a novel smoking cessation ...

The labs are not all right. After years of new supply without the tenant demand to support it, life sciences real estate nationwide is at an inflection point, with 18.7M SF likely to change uses by ...

On 20 January 2026, Ropes & Gray’s Global Life Sciences Regulatory & Compliance team hosted the “Life Sciences Regulatory Outlook 2026” webinar.